Agenda
January 23, 2009
Dallas, TX
| COMPREHENSIVE REVIEW OF LUNG CANCER
Dallas, TX - Friday, January 23, 2009 |
||
| 7:30 AM | BREAKFAST | |
| 8:25 AM | Welcome and Introductions | Chandra P. Belani, MD |
| Adjuvant Therapy and Multimodality Therapy
Session Chair: Chandra P. Belani, MD |
||
| 8:30 AM | Early Stage Non-Small cell Lung Cancer: Adjuvant and Neoadjuvant Therapy | Heather Wakelee, MD |
| 8:55 AM | Management of Stage III Disease: Multimodality Therap | Hak Choy, MD |
| 9:20 AM | Rethinking the Implication of Histology in the Treatment of Non?Small cell Lung Cancer | Corey Langer, MD |
| 9:45 AM | Panel Discussion | |
| 10:05 AM | BREAK | |
| Targeting VEGF and EGFR Receptors in Lung Cancer
Session Chair: Suresh Ramalingam, MD |
||
| 10:15 AM | Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors and Multikinase Inhibitors in the Treatment of Lung Cancer | Suresh Ramalingam, MD |
| 10:40 PM | Targeting Epidermal Growth Factor Receptor-Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors | Fred Hirsch, MD |
| 11:05 AM | Bevacizumab: Implications of Recent data in Non?Small-Cell Lung Cancer | Ronald Natale, MD |
| 11:30 AM | Panel Discussion | |
| 11:50 AM | LUNCH | |
| SState of the Art and Other Targeted Agents in Lung Cancer
Session Chair-Chandra P. Belani, MD |
||
| 12:50 PM | First-Line Chemotherapy Options in Advanced Disease | Chandra P. Belani, M |
| 1: 15 PM | Second-line Chemotherapeutic Options for Treatment of Lung Cancer | Ramaswamy Govindan, MD |
| 1:40 PM | Small-Cell Lung Cancer: Novel Agents and Recent Advances | Ronald Natale, MD |
| 2:05 PM | Novel Agents in Lung Cancer-HDAC Inhibitors, nab-Paclitaxel, and Bortezomib | Fadlo Khuri, MD |
| 2:30 PM | Panel Discussion | |
| 2:50 PM | Closing Remarks & Adjourn | Chandra P. Belani, M |